News for hackers. Stuff that matters.

A comment on Goldman Sachs questions whether curing patients is a sustainable business model. Parent comment

Re:Goldman Sachs questions whether curing patients is a sust... by EamonnMR on Friday April 13, 2018 @09:46AM (#16829903)
The barrier to entry is extremely high. There are regulatory hurdles, hurdles to being taken seriously, etc. You need authorization for human trials, you need to get published, you need to convince insurance companies to pay for your product.
[ Parent | on HN ]
Re:Goldman Sachs questions whether curing patients is a sust... by Bromskloss on Friday April 13, 2018 @04:13PM (#16833522)
The same as for the first drug manufacturer, I suppose. And if you really have a superior product, you should be able to take all the customers, assuming that the customers are smart enough.
[ Parent | on HN ]